BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38614860)

  • 1. Personalised follow-up and management schema for patients with screen-detected pulmonary nodules: A dynamic modelling study.
    Wang Z; Xue F; Sui X; Han W; Song W; Jiang J
    Pulmonology; 2024 Apr; ():. PubMed ID: 38614860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling.
    Gilbert FJ; Harris S; Miles KA; Weir-McCall JR; Qureshi NR; Rintoul RC; Dizdarevic S; Pike L; Sinclair D; Shah A; Eaton R; Clegg A; Benedetto V; Hill JE; Cook A; Tzelis D; Vale L; Brindle L; Madden J; Cozens K; Little LA; Eichhorst K; Moate P; McClement C; Peebles C; Banerjee A; Han S; Poon FW; Groves AM; Kurban L; Frew AJ; Callister ME; Crosbie P; Gleeson FV; Karunasaagarar K; Kankam O; George S
    Health Technol Assess; 2022 Mar; 26(17):1-180. PubMed ID: 35289267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignancy risk estimation of screen-detected nodules at baseline CT: comparison of the PanCan model, Lung-RADS and NCCN guidelines.
    van Riel SJ; Ciompi F; Jacobs C; Winkler Wille MM; Scholten ET; Naqibullah M; Lam S; Prokop M; Schaefer-Prokop C; van Ginneken B
    Eur Radiol; 2017 Oct; 27(10):4019-4029. PubMed ID: 28293773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the timing of diagnostic testing after positive findings in lung cancer screening: a proof of concept radiomics study.
    Wang Z; Li N; Zheng F; Sui X; Han W; Xue F; Xu X; Yang C; Hu Y; Wang L; Song W; Jiang J
    J Transl Med; 2021 May; 19(1):191. PubMed ID: 33947428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial.
    Li Q; Balagurunathan Y; Liu Y; Qi J; Schabath MB; Ye Z; Gillies RJ
    Clin Lung Cancer; 2018 Mar; 19(2):148-156.e3. PubMed ID: 29137847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for Reducing False-Positive Screening Results for Intermediate-Size Nodules Evaluated Using Lung-RADS: A Secondary Analysis of National Lung Screening Trial Data.
    Hammer MM; Hunsaker AR
    AJR Am J Roentgenol; 2022 Sep; 219(3):397-405. PubMed ID: 35319912
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer Risk in Subsolid Nodules in the National Lung Screening Trial.
    Hammer MM; Palazzo LL; Kong CY; Hunsaker AR
    Radiology; 2019 Nov; 293(2):441-448. PubMed ID: 31526256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Lung-Screening Reporting and Data System Versus Pan-Canadian Early Detection of Lung Cancer Nodule Risk Calculation in the Alberta Lung Cancer Screening Study.
    Tremblay A; Taghizadeh N; MacGregor JH; Armstrong G; Bristow MS; Guo LLQ; Lydell C; Pereira R; Lee A; Elliot T; MacEachern P; Graham A; Dickinson JA; Koetzler R; Lam SC; Yang H; Bédard EL; Tammemagi M; Burrowes P
    J Am Coll Radiol; 2019 Oct; 16(10):1425-1432. PubMed ID: 31103442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Prediction Models for Identifying Malignancy in Pulmonary Nodules Detected via Low-Dose Computed Tomography.
    González Maldonado S; Delorme S; Hüsing A; Motsch E; Kauczor HU; Heussel CP; Kaaks R
    JAMA Netw Open; 2020 Feb; 3(2):e1921221. PubMed ID: 32058555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparison of the PanCan Model and Lung-RADS to Assess Cancer Probability Among People With Screening-Detected, Solid Lung Nodules.
    Sundaram V; Gould MK; Nair VS
    Chest; 2021 Mar; 159(3):1273-1282. PubMed ID: 33393476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Radiomic Models Based on Low-Dose and Standard-Dose CT for Prediction of Adenocarcinomas and Benign Lesions in Solid Pulmonary Nodules.
    Liu J; Xu H; Qing H; Li Y; Yang X; He C; Ren J; Zhou P
    Front Oncol; 2020; 10():634298. PubMed ID: 33604303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recalibration of a Deep Learning Model for Low-Dose Computed Tomographic Images to Inform Lung Cancer Screening Intervals.
    Landy R; Wang VL; Baldwin DR; Pinsky PF; Cheung LC; Castle PE; Skarzynski M; Robbins HA; Katki HA
    JAMA Netw Open; 2023 Mar; 6(3):e233273. PubMed ID: 36929398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.
    Walter JE; Heuvelmans MA; de Jong PA; Vliegenthart R; van Ooijen PMA; Peters RB; Ten Haaf K; Yousaf-Khan U; van der Aalst CM; de Bock GH; Mali W; Groen HJM; de Koning HJ; Oudkerk M
    Lancet Oncol; 2016 Jul; 17(7):907-916. PubMed ID: 27283862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant Nodules Detected on Lung Cancer Screening CT: Yield of Short-Term Follow-Up CT in Showing Nodule Growth.
    Byrne SC; Hammer MM
    AJR Am J Roentgenol; 2022 Nov; 219(5):735-741. PubMed ID: 35674352
    [No Abstract]   [Full Text] [Related]  

  • 15. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.
    Horeweg N; van Rosmalen J; Heuvelmans MA; van der Aalst CM; Vliegenthart R; Scholten ET; ten Haaf K; Nackaerts K; Lammers JW; Weenink C; Groen HJ; van Ooijen P; de Jong PA; de Bock GH; Mali W; de Koning HJ; Oudkerk M
    Lancet Oncol; 2014 Nov; 15(12):1332-41. PubMed ID: 25282285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probability of cancer in pulmonary nodules detected on first screening CT.
    McWilliams A; Tammemagi MC; Mayo JR; Roberts H; Liu G; Soghrati K; Yasufuku K; Martel S; Laberge F; Gingras M; Atkar-Khattra S; Berg CD; Evans K; Finley R; Yee J; English J; Nasute P; Goffin J; Puksa S; Stewart L; Tsai S; Johnston MR; Manos D; Nicholas G; Goss GD; Seely JM; Amjadi K; Tremblay A; Burrowes P; MacEachern P; Bhatia R; Tsao MS; Lam S
    N Engl J Med; 2013 Sep; 369(10):910-9. PubMed ID: 24004118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial.
    Robbins HA; Katki HA; Cheung LC; Landy R; Berg CD
    J Thorac Oncol; 2019 Sep; 14(9):1662-1665. PubMed ID: 31125735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial.
    Marcus MW; Duffy SW; Devaraj A; Green BA; Oudkerk M; Baldwin D; Field J
    Thorax; 2019 Aug; 74(8):761-767. PubMed ID: 31028232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval.
    Silva M; Milanese G; Sestini S; Sabia F; Jacobs C; van Ginneken B; Prokop M; Schaefer-Prokop CM; Marchianò A; Sverzellati N; Pastorino U
    Eur Radiol; 2021 Apr; 31(4):1956-1968. PubMed ID: 32997182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated with a Positive Baseline Screening Exam Result in the National Lung Screening Trial.
    Balekian AA; Tanner NT; Fisher JM; Silvestri GA; Gould MK
    Ann Am Thorac Soc; 2016 Sep; 13(9):1568-74. PubMed ID: 27387658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.